BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 15790531)

  • 1. Metallothionein-mediated neuroprotection in genetically engineered mouse models of Parkinson's disease.
    Ebadi M; Brown-Borg H; El Refaey H; Singh BB; Garrett S; Shavali S; Sharma SK
    Brain Res Mol Brain Res; 2005 Mar; 134(1):67-75. PubMed ID: 15790531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metallothionein attenuates 3-morpholinosydnonimine (SIN-1)-induced oxidative stress in dopaminergic neurons.
    Sharma SK; Ebadi M
    Antioxid Redox Signal; 2003 Jun; 5(3):251-64. PubMed ID: 12880480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxynitrite in the pathogenesis of Parkinson's disease and the neuroprotective role of metallothioneins.
    Ebadi M; Sharma SK; Ghafourifar P; Brown-Borg H; El Refaey H
    Methods Enzymol; 2005; 396():276-98. PubMed ID: 16291239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease.
    Ebadi M; Sharma S
    Exp Biol Med (Maywood); 2006 Oct; 231(9):1576-83. PubMed ID: 17018883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons.
    Kooncumchoo P; Sharma S; Porter J; Govitrapong P; Ebadi M
    J Mol Neurosci; 2006; 28(2):125-41. PubMed ID: 16679553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complex-1 activity and 18F-DOPA uptake in genetically engineered mouse model of Parkinson's disease and the neuroprotective role of coenzyme Q10.
    Sharma SK; El Refaey H; Ebadi M
    Brain Res Bull; 2006 Jun; 70(1):22-32. PubMed ID: 16750479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
    Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
    Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
    Dong Z; Ferger B; Feldon J; Büeler H
    J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.
    Robertson DC; Schmidt O; Ninkina N; Jones PA; Sharkey J; Buchman VL
    J Neurochem; 2004 Jun; 89(5):1126-36. PubMed ID: 15147505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
    Schlüter OM; Fornai F; Alessandrí MG; Takamori S; Geppert M; Jahn R; Südhof TC
    Neuroscience; 2003; 118(4):985-1002. PubMed ID: 12732244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
    Vila M; Vukosavic S; Jackson-Lewis V; Neystat M; Jakowec M; Przedborski S
    J Neurochem; 2000 Feb; 74(2):721-9. PubMed ID: 10646524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-related biphasic effect of the Parkinson's disease neurotoxin MPTP, on the spread, accumulation, and toxicity of α-synuclein.
    Merghani MM; Ardah MT; Al Shamsi M; Kitada T; Haque ME
    Neurotoxicology; 2021 May; 84():41-52. PubMed ID: 33549656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
    Richfield EK; Thiruchelvam MJ; Cory-Slechta DA; Wuertzer C; Gainetdinov RR; Caron MG; Di Monte DA; Federoff HJ
    Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease?
    Youdim MB
    J Neural Transm Suppl; 2003; (65):73-88. PubMed ID: 12946050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased expression of serum- and glucocorticoid-inducible kinase 1 (SGK1) promotes alpha-synuclein increase related with down-regulation of dopaminergic cell in the Substantia Nigra of chronic MPTP-induced Parkinsonism mice and in SH-SY5Y cells.
    Yeo S; Sung B; Hong YM; van den Noort M; Bosch P; Lee SH; Song J; Park SK; Lim S
    Gene; 2018 Jun; 661():189-195. PubMed ID: 29604467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.
    Yang L; Calingasan NY; Wille EJ; Cormier K; Smith K; Ferrante RJ; Beal MF
    J Neurochem; 2009 Jun; 109(5):1427-39. PubMed ID: 19476553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.